A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model

British Journal of Radiology

Volumn 83, Issue 989, 2010, Pages 428-432

  Nitta, Norihisa ^a   Sonoda, A ^a   Seko, A ^a   Ohta, S ^a   Nagatani, Y ^a   Tsuchiya, K ^a   Otani, H ^a   Tanaka, T ^a   Kanasaki, S ^a   Takahashi, M ^a   Murata, K ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLAVOPIRIDOL; GELATIN; MICROSPHERE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ELUTION; LIVER TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROPER HEPATIC ARTERY; RABBIT; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLAVONOIDS; GELATIN; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MICROSPHERES; PIPERIDINES; RABBITS;

EID: 77951551332     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/17506834     Document Type: Article

References (26)

1. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, et al. A phase 2 trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage 4 non-small cell lung cancer. Clin Cancer Res 2001;7:1590-1598
2. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, et al. Phase 2 study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001;19:1985-1992
3. Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005;29:1253-1257
4. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
5. Bible KC, Lensing JL, Nelson SA, Lee YV, Reid JM, Ames MM, et al. Phase 1 trial flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005;11:5935-5941
6. Ohta S, Nitta N, Sonoda A, Seko A, Tanaka T, Takahashi M, et al. Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anti-cancer effect in rabbits. Eur J Radiol 2008: in press.
7. Ohta S, Nitta N, Sonoda A, Seko A, Tanaka T, Takahashi M, et al. Cisplatin-conjugated degradable gelatin microspheres: fundamental study in vitro. Br J Radiol 2009;82:380-385
8. Nitta N, Ohta S, Tanaka T, Takazakura R, Toyama T, Sonoda A, et al. An initial clinical study on the efficacy of cisplatin-releasing gelatin microspheres for metastatic liver tumors. Eur J Radiol 2009;71:519-526
9. Tabata Y, Ikada Y. Synthesis of gelatin microspheres containing interferon. Pharm Res 1989;6:422-427 (Pubitemid 19176088)
10. Ohta S, Nitta N, Takahashi M, Murata K, Tabata Y. Degradable gelatin microspheres as an embolic agent: an experimental study in a rabbit renal model. Korean I Radiol 2007;8:418-428
11. Ramirez LH, Zhao Z, Rougier P, Bognel C, Dzodic R, Vassal G, et al. Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits. Cancer Chemother Pharmacol 1996;37:371-376 (Pubitemid 26031016)
12. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, et al.Phase 1 trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1989;16:2986-2999
13. Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, et al. Phase 1 clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50:465-472
14. Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, et al. Phase 1 clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002;20:4074-4082
15. Grendys EC Jr, Blessing JA, Burger R, Hoffman J. A phase 2 evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: agynecologic oncology group study. Gynecol Oncol 2005;98:249-253 (Pubitemid 41019113)
16. Morris DG, Bramwell VHC, Turcotte R, Figueredo AT, Blackstein ME, Verma S, et al. A phase 2 study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma 2006;1-7.
17. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, et al. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 clinical and pharmacodynamic end-points. Heamatologica 2006;91:390-393
18. Van Veldhuizen PJ, Faulkner JR, Lana Jr PN, Gumerlock PH, Goodwin JW, Dakhil SR, et al. A phase 2 study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol 2005;56:39-45. (Pubitemid 41201754)
19. Aklilu M, Kindler H, Donehower RC, Mani S, Vokes EE. Phase 2 study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003;14:1270-1273 (Pubitemid 37039054)
20. Liu G, Gandara DR, Lara PN Jr, Raghavan D, Doroshow JH, Twardowski P, et al. A phase 2 trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004;10:924-928
21. Bible K, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005;11:5935-5941
22. El-Rayes BF, Gadgeel S, Parchment R, Lorusso P, Philip PA. A phase 1 study of flavopiridol and docetaxel. Invest New Drugs 2006;24:305-310
23. Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, et al. A phase 1 clinical trial of the sequential combination of irrinotecan followed by flavopiridol. Clin Cancer Res 2005;11:3836-3845
24. George S, Kasimis BS, Cogswell J, Schwarzenberger P, Shapiro GI, Fidias P, et al. Phase 1 study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer 2008;9:160-165 (Pubitemid 351880855)
25. Karp JE, Smith D, Levis MJ, Gore SD, Greer J, Hattenburg C, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase 2 trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007;13:4467-4473
26. Nitta N, Ohta S, Tanaka T, Takazakura R, Nagatani Y, Kono N, et al. Gelatin microspheres: initial clinical experience for the transcatheter arterial embolization. Eur J Radiol 2008;67:536-540